News
Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks Therapeutics, which is being repped by Goodwin Procter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback